Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

(2012) V. A. Fonseca et al.   DIABETES CARE

Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes

(2011) M. Riddle et al.   DIABETES CARE

Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes

(2011) Kohei Kaku et al.   Journal of Diabetes Investigation

Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial

(2011) Yutaka Seino et al.   Journal of Diabetes Investigation

Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes

(2011) Nobuya Inagaki et al.   Journal of Diabetes Investigation

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes

(2011) Daisuke Yabe et al.   Journal of Diabetes Investigation

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

(2010) Y. Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl

(2010) W. Yang et al.   DIABETES OBESITY & METABOLISM

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

(2010) R. E. Ratner et al.   DIABETIC MEDICINE

The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes

(2010) D. Russell-Jones   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

(2010) Ulrich Werner et al.   REGULATORY PEPTIDES

Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks

(2010) Takashi Kadowaki et al.   Journal of Diabetes Investigation

GIP and GLP-1, the two incretin hormones: Similarities and differences

(2010) Yutaka Seino et al.   Journal of Diabetes Investigation

Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

(2010) Daisuke Yabe et al.   Journal of Diabetes Investigation

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results

(2009) Sten Madsbad   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

(2009) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes

(2009) Takashi KADOWAKI et al.   ENDOCRINE JOURNAL

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

(2008) Y. Seino et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea

(2008) Yan Gao et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations

(2008) A. Ceriello et al.   DIABETIC MEDICINE